Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a

May, Matthias; Bastian, Patrick J.; Brookman‐May, Sabine; Fritsche, Hans‐Martin; Tilki, Derya; Otto, Wolfgang; Bolenz, Christian; Gilfrich, Christian; Trojan, Lutz; Herrmann, Edwin; Moritz, Rudolf; Tiemann, Arne; Müller, Stefan; Ellinger, Jörg; Büchner, Alexander; Stief, Christian G.; Wieland, Wolf F.; Höfner, Thomas; Hohenfellner, Markus; Haferkamp, Axel; Roigas, Jan; Zacharias, Mario; Nuhn, Philipp; Burger, Maximilian

doi:10.1016/j.urolonc.2011.09.011

Cited by 56 publications

(61 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anatomical differences in staging also result ultimately in differences in outcomes following radical cystectomy. Several studies have demonstrated worse recurrence‐free survival and cancer‐specific survival in pT4a females following radical cystectomy compared to pT4a males …”

Section: Stage Pt4 Carcinomamentioning

confidence: 99%

Staging of bladder cancer

et al. 2018

View full text Add to dashboard Cite

Urothelial carcinoma of the urinary bladder is a heterogeneous disease with multiple possible treatment modalities and a wide spectrum of clinical outcome. Treatment decisions and prognostic expectations hinge on accurate and precise staging, and the recently published American Joint Committee on Cancer (AJCC) Staging Manual, 8th edition, should be the basis for staging of urinary bladder tumours. It is unfortunate that the International Union Against Cancer (UICC) 8th edition failed to incorporate new data which is considered in the AJCC 8th edition. Thus, the AJCC 8th edition is the focus of this review. Several critical changes and clarifications are made by the AJCC 8th edition relative to the 7th edition. Although the most obvious changes in the 8th edition are in the N (i.e. perivesical lymph node involvement now classified as N1) and M (i.e. M1 is subdivided into M1a and M1b) categories, several points are clarified in the T category (e.g. substaging of pT1 should be attempted). Further optimisation, however, is required. No particular method of substaging pT1 is formally recommended. In this review, these modifications are discussed, as well as points, which require further study and optimisation.

show abstract

Section: Stage Pt4 Carcinomamentioning

confidence: 99%

Staging of bladder cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…As well as being less likely to have a radical cystectomy for MIBC [34,] women historically were less likely to receive continent urinary diversion (3 vs. 49% of men) [35]. More recently, the proportion of women having cystectomy has significantly increased, approaching that of men: 18% in 1989-1996 to 44.4% in 2003-2008 as reported by Otto et al [36] and 36% in 1992-1999 to 63.9% in 2000-2007 as reported by May et al [37].…”

Section: Does Type Of Treatment Received Differ Between Genders?mentioning

confidence: 99%

“…Worse outcomes for women following radical cystectomy are well documented [18,29,35,36,37,44,45] but these findings are refuted by Mitra et al [8.] Having intensively matched 414 female and male cystectomy patients for demographic, tumor and treatment characteristics, no significant difference in recurrence-free survival, cancer-specific survival or overall survival was found (p = 0.45, p = 0.34, p = 0.71, respectively).…”

Section: Does Response To Treatment Differ Between Genders? - What Ismentioning

confidence: 99%

Closing the Gender Gap: Can We Improve Bladder Cancer Survival in Women? - A Systematic Review of Diagnosis, Treatment and Outcomes

Burge

Kockelbergh

2016

Urol Int

View full text Add to dashboard Cite

Introduction: Despite recent attention, there are no gender specific guidelines to address the disparity in bladder cancer survival between the sexes. The focus of this review was to identify areas of clinical practice that may influence bladder cancer outcomes and to provide evidence-based recommendations to improve bladder cancer survival in women. Method: A systematic search of MEDLINE was conducted to identify studies related to referral, diagnosis, treatment and outcomes of patients with bladder cancer with particular reference to gender differences. Results: Patients' knowledge of key signs and symptoms of bladder cancer is poor. There is evidence that there is a gender difference in referral patterns both at patient and primary care level. The presence of cystits, in particular, delays referral. Treatment and surveillance of high-risk non-muscle invasive cancers is variable and non-urothelial bladder cancer, which has higher incidence in women is more likely to be treated non-operatively than urothelial bladder cancer. Conclusion: We have offered recommendations to improve patient education and streamline referrals and suggested considerations for treatment of high-risk cancers to help improve survival in female bladder cancer patients.

show abstract

“…Better survival in men may be partly attributable to the structure of the male lower urinary tract: higher pressures within the male bladder due to the presence of the prostate gland and a stronger detrusor muscle may obstruct metastatic spread and lymphatic [22][23][24][25]. It is unlikely that the difference can be explained entirely by the more frequent diagnosis of higher stages at first presentation among women [26].…”

Section: Urinary Bladder Cancersmentioning

confidence: 99%